These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25935549)

  • 41. Expression of the T-cell regulatory marker FOXP3 in primary cutaneous large B-cell lymphoma tumour cells.
    Felcht M; Heck M; Weiss C; Becker JC; Dippel E; Müller CS; Nashan D; Sachse MM; Nicolay JP; Booken N; Goerdt S; Klemke CD
    Br J Dermatol; 2012 Aug; 167(2):348-58. PubMed ID: 22512270
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upregulation of miRNA-17 and miRNA-19 is associated with unfavorable prognosis in patients with T-cell lymphoblastic lymphoma.
    Xi Y; Li J; Zhang P; Bai W; Gao N; Bai W; Zhang Y; Wu Y; Ning Y
    Exp Mol Pathol; 2015 Oct; 99(2):297-302. PubMed ID: 26231295
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical relevance of elevated levels of serum soluble interleukin-2 receptor alpha (sIL-2Rα) in patients with non-Hodgkin's lymphoma.
    Jo SA; Hwang SH; Chang CL; Kim SY; Shin HJ; Chung JS; Sol MY; Lee EY
    Korean J Lab Med; 2010 Dec; 30(6):600-5. PubMed ID: 21157146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Significance of soluble interleukin-2 receptor alpha chain in the management of patients with malignant lymphoma: a multi-center study].
    Ohno H; Ishikawa T; Kitajima H; Nomura S; Suzuki T; Konishi H; Ohno Y; Onishi R; Konaka Y; Arima N; Doi S; Nasu K; Takahashi T; Tsudo M; Fukuhara S; Uchiyama T
    Rinsho Ketsueki; 2002 Mar; 43(3):170-5. PubMed ID: 11979748
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Correlation between peripheral blood CD4+CD25high CD127low regulatory T cell and clinical characteristics of patients with non-Hodgkin's lymphoma.
    Lin H; Sun XF; Zhen ZJ; Xia Y; Ling JY; Huang HQ; Xia ZJ; Lin TY
    Ai Zheng; 2009 Nov; 28(11):1186-92. PubMed ID: 19895740
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating soluble interleukin-2 receptor alpha and beta chain in inflammatory bowel disease.
    Nielsen OH; Ciardelli T; Wu Z; Langholz E; Kirman I
    Am J Gastroenterol; 1995 Aug; 90(8):1301-6. PubMed ID: 7639234
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
    El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
    Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the levels of serum-soluble interleukin-2 receptor after surgical stress.
    Murakami S; Sakata H; Tsuji Y; Okubo K; Takahashi T; Kikuchi M; Hirayama R
    Surg Today; 2003; 33(8):565-70. PubMed ID: 12884092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic significance of serum soluble interleukin-2 receptor level in non-Hodgkin's lymphoma: a single center study in Japan.
    Kono N; Kanda Y; Yamamoto R; Chizuka A; Suguro M; Hamaki T; Arai C; Matsuyama T; Takezako N; Miwa A; Togawa A
    Leuk Lymphoma; 2000 Mar; 37(1-2):151-6. PubMed ID: 10721779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Elevated soluble IL-2 receptor levels correlate with tumor bulk of follicular lymphomas with intestinal involvement.
    Iwamuro M; Shinagawa K; Okada H; Takata K; Yoshino T; Yamamoto K
    Clin Biochem; 2014 Feb; 47(3):191-5. PubMed ID: 24362271
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Soluble interleukin-2 receptors in sera of children with primary malignant neoplasms.
    Bodey B; Psenko V; Lipsey AL; Kaiser HE
    Anticancer Res; 1996; 16(1):219-24. PubMed ID: 8615612
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lymphoblastic lymphoma.
    Cortelazzo S; Ponzoni M; Ferreri AJ; Hoelzer D
    Crit Rev Oncol Hematol; 2011 Sep; 79(3):330-43. PubMed ID: 21273093
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.
    Heemann C; Kreuz M; Stoller I; Schoof N; von Bonin F; Ziepert M; Löffler M; Jung W; Pfreundschuh M; Trümper L; Kube D
    Clin Cancer Res; 2012 Jul; 18(13):3637-47. PubMed ID: 22573350
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab.
    ter Meulen CG; Göertz JH; Klasen IS; Verweij CM; Hilbrands LB; Wetzels JF; Hoitsma AJ
    Kidney Int; 2003 Aug; 64(2):697-703. PubMed ID: 12846768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B-lineage lymphoblastic lymphoma is a clinicopathologic entity distinct from other histologically similar aggressive lymphomas with blastic morphology.
    Soslow RA; Baergen RN; Warnke RA
    Cancer; 1999 Jun; 85(12):2648-54. PubMed ID: 10375114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elevated serum levels of soluble interleukin-2 receptor: a marker of disease activity in the hypereosinophilic syndrome.
    Prin L; Plumas J; Gruart V; Loiseau S; Aldebert D; Ameisen JC; Vermersch A; Fenaux P; Bletry O; Capron M
    Blood; 1991 Nov; 78(10):2626-32. PubMed ID: 1726707
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The serum levels of soluble interleukin-2 receptor alpha and lactate dehydrogenase but not of B2-microglobulin correlate with selected clinico-pathological prognostic factors and response to therapy in childhood soft tissue sarcomas.
    Bien E; Rapala M; Krawczyk M; Balcerska A
    J Cancer Res Clin Oncol; 2010 Feb; 136(2):293-305. PubMed ID: 19693535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma.
    Vonderheid EC; Zhang Q; Lessin SR; Polansky M; Abrams JT; Bigler RD; Wasik MA
    J Am Acad Dermatol; 1998 Feb; 38(2 Pt 1):207-20. PubMed ID: 9486676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of Soluble Interleukin 2 Receptor in Sera of Adult Patients with Hematological or Solid Malignancies.
    Delforge A; Bernier M; Bosmans E; Massy M; Bron D; Heyligen H; Raus J; Mendes Da Costa P; Stryckmans P
    Leuk Lymphoma; 1991; 3(5-6):385-93. PubMed ID: 27467429
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aggressive non-Hodgkin's lymphoma: concomitant evaluation of interleukin-2, soluble interleukin-2 receptor, interleukin-4, interleukin-6, interleukin-10 and correlation with outcome.
    Fabre-Guillevin E; Tabrizi R; Coulon V; Monnereau A; Eghbali H; Soubeyran I; Soubeyran P
    Leuk Lymphoma; 2006 Apr; 47(4):603-11. PubMed ID: 16690518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.